Abstract
This chapter provides information on the history and development of botulinum neurotoxins as a therapeutic tool in clinical medicine. It discusses the contributions of pioneers of this field as well as contribution of contemporary scientists and clinicians.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Whitcup SM. The history of botulinum toxins in medicine: a thousand year journey. Handb Exp Pharmacol. 2019. https://doi.org/10.1007/164_2019_271.
Erbguth FJ. Botulinum toxin, a historical note. Lancet. 1998;351(9118):1820. https://doi.org/10.1016/S0140-6736(05)78793-6.
Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004;19(Suppl 8):S2–6. https://doi.org/10.1002/mds.20003.
Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna). 2008;115(4):559–65. https://doi.org/10.1007/s00702-007-0728-2.
Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109(1–2):10–24. https://doi.org/10.1113/jphysiol.1949.sp004364.
Drachman DB. Atrophy of skeletal muscles in chicks embryo treated with botulinum toxin. Science. 1964;145(3633):719–21. https://doi.org/10.1126/science.145.3633.719.
Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17(1):21–5.
Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22(2):131–v. https://doi.org/10.1016/s0733-8635(03)00019-6.
Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131–8. https://doi.org/10.1002/mds.27072.
Jabbari B. Botulinum toxins in pain disorders. Springer; 2015.
Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359(6398):832–5. https://doi.org/10.1038/359832a0.
Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992;267(33):23479–83.
Caleo M, Spinelli M, Colosimo F, et al. Transynaptic action of botulinum neurotoxin type A at central cholinergic boutons. J Neurosci. 2018;38(48):10329–37. https://doi.org/10.1523/JNEUROSCI.0294-18.2018.
Filipović B, Matak I, Bach-Rojecky L, Lacković Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One. 2012;7(1):e29803. https://doi.org/10.1371/journal.pone.0029803.
Matak I. Evidence for central antispastic effect of botulinum toxin type A. Br J Pharmacol. 2020;177(1):65–76. https://doi.org/10.1111/bph.14846.
Wang J, Casals-Diaz L, Zurawski T, et al. A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain. Neuropharmacology. 2017;118:223–32. https://doi.org/10.1016/j.neuropharm.2017.03.026.
Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160–3. https://doi.org/10.1038/365160a0.
Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36. https://doi.org/10.1111/j.1526-4610.2010.01678.x.
Wissel J, Bensmail D, Ferreira JJ, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology. 2017;88(14):1321–8. https://doi.org/10.1212/WNL.0000000000003789.
Dressler D, Roggenkaemper P. A brief history of neurological botulinum toxin therapy in Germany. J Neural Transm (Vienna). 2017;124(10):1217–21. https://doi.org/10.1007/s00702-017-1762-3.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jabbari, B. (2022). The History of Botulinum Neurotoxin Development. In: Botulinum Toxin Treatment of Pain Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-99650-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-99650-5_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-99649-9
Online ISBN: 978-3-030-99650-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)